First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis

First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis

ObjectivePrognosis of patients with irresectable cholangiocarcinoma is still poor. The ABC-02 trial established the current first line (1L) standard systemic chemotherapy (CT) with gemcitabine/platinum derivate for advanced cholangiocarcinoma. However, the majority of patients needed therapy adaptio...

Full description

Bibliographic Details
Main Authors: Christian Möhring, Jan Feder, Raphael U. Mohr, Farsaneh Sadeghlar, Alexandra Bartels, Robert Mahn, Taotao Zhou, Milka Marinova, Georg Feldmann, Peter Brossart, Martin von Websky, Hanno Matthaei, Steffen Manekeller, Tim Glowka, Jörg C. Kalff, Tobias J. Weismüller, Christian P. Strassburg, Maria A. Gonzalez-Carmona
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-11-01
Series:Frontiers in Oncology
Subjects:
bile duct carcinoma
cholangiocellular carcinoma
first line palliative chemotherapy
second line palliative chemotherapy
retrospective analysis
gemcitabine/cisplatin
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.717397/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.717397/full

Similar Items